文献速递认知障碍与痴呆

APOE与阿尔茨海默病:遗传学、病理生理学及治疗进展

APOE and Alzheimer's disease: advances in genetics, pathophysiology, and therapeutic approaches.
PubMed 文献 · Lancet Neurol · 2021-01-01

本文综述了APOE ε4等位基因作为散发性阿尔茨海默病最强遗传风险因素及ε2等位基因保护作用的证据,指出近五年对APOE致病机制的理解已从β淀粉样肽中心扩展至tau神经纤维变性、胶质细胞反应和血脑屏障破坏。多种靶向APOE的治疗策略在表达人APOE等位基因的小鼠模型中成功,但向人类临床试验转化仍具挑战性。

要点

  • APOE ε4是散发性阿尔茨海默病最强遗传风险因素,ε2是最强遗传保护因素。
  • APOE致病机制已扩展至tau变性、胶质细胞反应和血脑屏障破坏。
  • 靶向APOE的小鼠模型治疗成功,但人类临床试验转化困难。

核心结论

  • APOE ε4等位基因仍是散发性阿尔茨海默病最强的遗传风险因素,APOE ε2等位基因是最强的遗传保护因素。
  • 目前尚无针对APOE的疗法可用。
  • 对APOE致病机制的理解已从β淀粉样肽中心机制扩展至tau神经纤维变性、小胶质细胞和星形胶质细胞反应以及血脑屏障破坏。

研究设计与样本

  • 综述性文章,基于多项大规模全基因组关联研究和全基因组关联荟萃分析。

主要发现

  • APOE ε4等位基因是散发性阿尔茨海默病最强的遗传风险因素,APOE ε2等位基因是最强的遗传保护因素。
  • 近五年对APOE病理生理学的理解已超越β淀粉样肽中心机制,扩展至tau神经纤维变性、小胶质细胞和星形胶质细胞反应以及血脑屏障破坏。
  • 多种治疗策略在表达人APOE等位基因的小鼠模型中成功,包括增加或降低APOE水平、增强其脂化、阻断APOE与β淀粉样肽相互作用以及将APOE4基因转换为APOE3或APOE2亚型,但向人类临床试验转化具有挑战性。

临床怎么用

  • 应利用关于APOE病理生理学的新知识开发针对APOE的疗法。
  • 针对APOE的治疗策略在动物模型中显示成功,但需克服向人类临床试验转化的挑战。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The APOE ε4 allele remains the strongest genetic risk factor for sporadic Alzheimer's disease and the APOE ε2 allele the strongest genetic protective factor after multiple large scale genome-wide association studies and genome-wide association meta-analyses. However, no therapies directed at APOE are currently available. Although initial studies causally linked APOE with amyloid-β peptide aggregation and clearance, over the past 5 years our understanding of APOE pathogenesis has expanded beyond amyloid-β peptide-centric mechanisms to tau neurofibrillary degeneration, microglia and astrocyte responses, and blood-brain barrier disruption. Because all these pathological processes can potentially contribute to cognitive impairment, it is important to use this new knowledge to develop therapies directed at APOE. Several therapeutic approaches have been successful in mouse models expressing human APOE alleles, including increasing or reducing APOE levels, enhancing its lipidation, blocking the interactions between APOE and amyloid-β peptide, and genetically switching APOE4 to APOE3 or APOE2 isoforms, but translation to human clinical trials has proven challenging.

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. Serrano-Pozo A, Das S, Hyman BT, et al. APOE and Alzheimer's disease: advances in genetics, pathophysiology, and therapeutic approaches. Lancet Neurol. 2021. PMID: 33340485. doi:10.1016/S1474-4422(20)30412-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。